Comparing the Effects of Spironolactone With Chlortalidone on LV Mass in Patients With CKD

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 154 participants.

Also called NCT02502981

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 154 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02502981
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02502981. Allocation not applicable; no masking; primary purpose treatment. Start 2014-06 (registry gives no type); primary completion 2018-02 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparing the Effects of Spironolactone With Chlortalidone on LV Mass in Patients With CKD
Acronym
SPIRO-CKD
Condition
Renal Insufficiency, Chronic
Condition
Cardio-Renal Syndrome
Intervention (Drug)
Spironolactone
Intervention (Drug)
Chlortalidone
Lead sponsor
University Hospital Birmingham (class: other)
Collaborator
Royal Free Hospital NHS Foundation Trust (class: other)
Collaborator
University of Edinburgh (class: other)
Collaborator
University of Cambridge (class: other)

Record details

Record id
cardio:ct-nct02502981
Content hash
a0c9904acb0291ad93de172d35d00363b2bd9356fb96d77e3ce9dc9fe2c23f44